Literature DB >> 12227701

Surgical treatment of malignant tumors of the right heart.

Hiroshi Kubota1, Shinichi Takamoto, Yutaka Kotsuka, Tsuyoshi Miyairi, Tomohiro Murakawa, Haruo Makuuchi, Motohiro Kawauchi, Akira Furuse, Kenichi Sudo.   

Abstract

Seven patients with malignant cardiac tumors were treated surgically in the Department of Cardiothoracic Surgery of the University of Tokyo between 1981 and 2000. Their treatments and outcomes are summarized and discussed. The ages of the patients ranged from 21 to 70 years old (mean: 49.5+/-15) and there were three males and four females. The histopathological diagnoses were hepatocellular carcinoma (HCC), spindle cell sarcoma, round cell sarcoma, osteosarcoma, renal cell carcinoma, and leiomyosarcoma. In four of the cases, the tumor extended or metastasized from other organs, while in the other three cases it originated in the heart. Before the cardiac operation, an above-knee amputation, left nephrectomy, transarterial embolization, or extended right hepatic lobectomy had been performed to treat the primary site of the tumor. Tumor resection using cardiopulmonary bypass was performed in every case. The NYHA classification of heart failure was significantly improved (preop: 3.3+/-0.8, postop: 1.9+/-0.7 [P<0.001]). The mean survival period of the patients who died was 8.8+/-7.0 months. A patient with renal cell carcinoma is still alive after 87 months of follow-up. In summary, surgical treatment of malignant tumors of the right heart can improve the QOL in patients with cardiac failure. However, its effectiveness was temporary in all cases except one case of renal cell carcinoma.

Entities:  

Mesh:

Year:  2002        PMID: 12227701     DOI: 10.1536/jhj.43.263

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  1 in total

1.  Clinical implication of surgical resection for the rare cardiac tumors involving heart and great vessels.

Authors:  Se Jin Oh; Sang Yoon Yeom; Kyung-Hwan Kim
Journal:  J Korean Med Sci       Date:  2013-05-02       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.